Differential Behavioral Effects of Gonadal Steroids in Women with and in Those without Premenstrual Syndrome

Schmidt, Peter J.; Nieman, Lynnette K.; Danaceau, Merry A.; Adams, Lowell; Rubinow, David R.

doi:10.1056/nejm199801223380401

Cited by 618 publications

(374 citation statements)

References 22 publications

Supporting

Mentioning

331

Contrasting

Unclassified

Order By: Relevance

“…However, findings from Bloch and colleagues (2000) demonstrating that administration and withdrawal of supraphysiologic doses of estradiol and progesterone sufficient to mimic pregnancy and the puerperium, respectively, provide clear evidence that PPD can be triggered by hormonal changes but only in certain subgroups of vulnerable women. These findings are consistent with those from the same group showing that sensitivity to hormonal perturbations characterize women with premenstrual dysphoric disorder (PMDD; Schmidt et al 1998). The mechanism for this vulnerability to mood disorders during times of hormonal change is not yet known but could include genetic, psychosocial and developmental factors.…”

Section: Introductionsupporting

confidence: 93%

Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study

et al. 2006

View full text Add to dashboard Cite

This study is the first to describe reductions in occipital cortex GABA levels in the postpartum period, a time of increased vulnerability to mood disturbances in women. The concomitant reduction in peripheral ALLO levels provides further evidence of alterations in the balance between cortical excitation and inhibition during the puerperium. Women with PPD may represent a subgroup of women who fail to adequately adapt to this alteration in the neuroendocrine milieu.

show abstract

Section: Introductionsupporting

confidence: 93%

Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study

et al. 2006

View full text Add to dashboard Cite

show abstract

“…However, this group of women reported similar improvement during treatment with placebo and 30 mg/day, and the impact of these mood scores are not clear. A similar effect of estradiol has, however, been reported in women with PMDD receiving estradiol while on gonadotropin-releasing hormone (GnRH) agonist to inhibit ovarian endogenous hormone production (Schmidt et al 1998).…”

Section: Discussionmentioning

confidence: 91%

Allopregnanolone concentration and mood—a bimodal association in postmenopausal women treated with oral progesterone

Andréen¹,

Sundström‐Poromaa

Bixo³

et al. 2006

Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…also review in 24]and 25]. Schmidt et al [26]suggest that symptoms of premenstrual disorder (PMS) may represent an abnormal response to normal hormonal changes in women with PMS. This finding, therefore, implicates cellular mechanisms downstream of estrogen receptors, rather than fluctuations in hormone levels, in mediating symptoms of PMS.…”

Section: Introductionmentioning

confidence: 99%

Estrogen Modulation of the Cyclic AMP Response Element-Binding Protein Pathway

Carlstrom¹,

Zhang²,

Unnerstall³

et al. 2001

Neuroendocrinology

View full text Add to dashboard Cite

Actions of estrogen include mechanisms leading to alterations in gene transcription that may be independent of nuclear estrogen receptors, as well as those involving direct action of the estrogen receptor on the genome. Also, the influence of estrogen in the brain appears to extend well beyond areas associated with reproduction and may include forebrain areas linked to affective and cognitive behaviors. We investigated the effects of acute and long-term estradiol benzoate (E2) treatment on total and phosphorylated cyclic AMP responsive element-binding (CREB) protein levels and on cyclic AMP response element (CRE)-DNA binding in forebrain areas of ovariectomized (OVX) rats. Long-term E2 treatment increased CRE-DNA binding in the amygdala but not in hippocampus, frontal cortex, or cerebellum. The increase in CRE-DNA binding in the amygdala was associated with increased levels of total and phosphorylated CREB (pCREB) protein during protracted E2 exposure. To localize the estrogenic effect in the amygdala and determine if an effect in one hippocampal region was masked by a lack of effect in another subregion, we performed immunolabeling of pCREB in brain structures of chronically treated OVX animals with or without E2. This treatment resulted in a significant increase in relative total immunolabeled nuclei in the anteroventral subdivision of the medial amygdala. In the hippocampus, a significant increase in relative total immunolabeled nuclei was seen in the CA1 and CA3 regions, but not in the dentate gyrus or hilus of the dentate gyrus. Acute E2 treatment resulted in increased CRE-DNA binding in the frontal cortex but not in amygdala, hippocampus, or cerebellum. However, no changes in levels of total CREB or pCREB protein were observed in the frontal cortex under E2 treatment. No changes were observed either in basal or cAMP-stimulated protein kinase A (PKA) activity or in PKA-α catalytic subunit immunoreactivity in the amygdala or the frontal cortex. Our study indicates that both long-term and acute treatments with estrogens influence the function of CREB in specific brain structures.

show abstract

Differential Behavioral Effects of Gonadal Steroids in Women with and in Those without Premenstrual Syndrome

Abstract: In women with premenstrual syndrome, the occurrence of symptoms represents an abnormal response to normal hormonal changes.

Cited by 618 publications

References 22 publications

Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study

Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study

Allopregnanolone concentration and mood—a bimodal association in postmenopausal women treated with oral progesterone

Estrogen Modulation of the Cyclic AMP Response Element-Binding Protein Pathway

Contact Info

Product

Resources

About